Transepithelial Accelerated Crosslinking for Progressive Keratoconus: A Critical Analysis of Medium-Term Treatment Outcomes.
Rodrigo Vilares-MorgadoAna Margarida FerreiraAna Maria CunhaRaúl MoreiraLuís TorrãoPedro Neves CardosoJoão Pinheiro-CostaPublished in: Clinical ophthalmology (Auckland, N.Z.) (2024)
TE-ACXL proved to be a safe therapeutic option for progressive KC. However, its efficacy is deemed unsatisfactory, as a notable proportion of affected eyes may continue to advance within a 4-year timeframe, necessitating additional procedures to halt the disease's course.